CUV 0.41% $14.53 clinuvel pharmaceuticals limited

Ann: Chair Letter to Shareholders, page-10

  1. 1,095 Posts.
    lightbulb Created with Sketch. 478
    if you’ve only researched Clinuvel for two days you’ll probably need to study a little bit longer. EPP is only the first orphan indication off the rank. With 40% yoy growth coupled with application for marketing to be submitted in Japan and Australia closely followed by XP and variagte porphyria indication extensions I don’t see $75mil sustained revenue being a problem. Add in vitiligo and the numbers are off the charts. Add in all dermatoses including Hailey-Hailey disease reaching large population numbers with reduced per unit price and we will have a monolithic company...
 
watchlist Created with Sketch. Add CUV (ASX) to my watchlist
(20min delay)
Last
$14.53
Change
-0.060(0.41%)
Mkt cap ! $730.6M
Open High Low Value Volume
$14.76 $14.76 $14.46 $297.3K 20.40K

Buyers (Bids)

No. Vol. Price($)
4 74 $14.49
 

Sellers (Offers)

Price($) Vol. No.
$14.53 44 2
View Market Depth
Last trade - 10.42am 31/07/2024 (20 minute delay) ?
CUV (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.